Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy

Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia

(2014) Robert T Jones et al.   MODERN PATHOLOGY

Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma

(2014) D. J. Panka et al.   MOLECULAR CANCER THERAPEUTICS

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas

(2014) Priscilla K Brastianos et al.   NATURE GENETICS

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

(2013) Paolo A. Ascierto et al.   JOURNAL OF CLINICAL ONCOLOGY

The superiority of conservative resection and adjuvant radiation for craniopharyngiomas

(2012) Adam Schoenfeld et al.   JOURNAL OF NEURO-ONCOLOGY

Absolute quantification of somatic DNA alterations in human cancer

(2012) Scott L Carter et al.   NATURE BIOTECHNOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009

(2012) T. A. Dolecek et al.   NEURO-ONCOLOGY

BRAF Inhibition in Refractory Hairy-Cell Leukemia

(2012) Sascha Dietrich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE